Novo Nordisk stock faces US setback over weekly insulin bid
Published on 11/12/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory setback meets obesity momentum
- The US weekly basal-insulin application has hit a major hurdle, putting additional focus on Novo Nordisk's diabetes pipeline.
- The FDA's GLP-1 labeling action adds a safety consideration for Wegovy and Ozempic as Novo defends their benefit-risk profile.
- The oral Wegovy rollout and the company's updated 2026 outlook remain important drivers for the investment case.
Novo Nordisk faces a fresh US regulatory setback after the Food and Drug Administration rejected its application for a once-weekly basal insulin on Wednesday, November 11. The decision affects a pipeline project intended to reduce the number of basal-insulin injections for people with diabetes, according to pharmaphorum.
Weekly insulin bid hits hurdle
The application concerned a basal insulin designed for once-weekly use rather than daily administration. The rejection initially blocks a US launch and places greater emphasis on the remaining development work in Novo Nordisk's diabetes portfolio.
The outcome does not determine the prospects of every research programme at the Danish drugmaker. It does, however, add a concrete development risk as investors assess the balance between established products, pipeline projects and intensifying competition in diabetes and obesity medicines.
Safety scrutiny adds another risk
The FDA also required new warnings for GLP-1 medicines over a potential risk of nonarteritic anterior ischemic optic neuropathy, or NAION, on Monday, November 9. Novo Nordisk said the available evidence does not establish a cause-and-effect relationship and reaffirmed confidence in the benefit-risk profile of its medicines, according to AD HOC NEWS.
Wegovy remains the growth test
The regulatory setbacks contrast with continued commercial focus on Wegovy. Novo Nordisk has expanded its oral Wegovy rollout into new markets, while its updated 2026 outlook calls for adjusted sales and adjusted operating profit growth between minus 2 percent and plus 2 percent at constant exchange rates.
Novo Nordisk stock traded at 36.80 euros on Lang & Schwarz at 17:31 CET on Thursday, November 12, 2026. That was 1.45 percent below the 37.34-euro quote cited in the prior report at 12:20 CET on the same day; this comparison is separate from the daily Xetra close.
Novo Nordisk A/S at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Lang & Schwarz price: 36.80 euros at 17:31 CET on Thursday, November 12, 2026
- Change since prior report: Minus 1.45 percent from 37.34 euros at 12:20 CET on November 12, 2026
- Regulatory issue: US rejection of a once-weekly basal-insulin application
European healthcare stocks remain relevant for the broader market context; see current market reports.
